Simulations Plus Releases Redesigned NAFLDsym® QSP Software Tool

Rhea-AI Summary

Simulations Plus (NASDAQ: SLP) has launched NAFLDsym v2B Beta, a new version of its quantitative systems pharmacology modeling software aimed at enhancing treatment development for nonalcoholic steatohepatitis (NASH). This release features a faster and more intuitive interface, developed using the Julia programming language, which significantly increases simulation speeds for large datasets. Key updates include a modern GUI, integration with the Julia toolkit, and a results viewer for previously exported files. A tech talk webinar on this release is scheduled for March 14, 2023, at 11:00 a.m. Eastern Time.

Positive

• The launch of NAFLDsym v2B Beta enhances drug development capabilities for NASH.
• Significant increase in simulation speed improves predictive capabilities.
• Intuitive user interface design improves user experience.
• Integration with modern technologies (Julia language and C++ GUI) enhances efficiency.

Negative

• None.

NAFLDsym v2B Beta represents the first release in the faster, sleeker Julia infrastructure

LANCASTER, Calif.--(BUSINESS WIRE)-- Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced the release of NAFLDsym v2B Beta, a quantitative systems pharmacology (QSP) modeling software to support the development of treatments for nonalcoholic steatohepatitis (NASH). This release focused solely on updates to the software infrastructure of NAFLDsym to enable a more intuitive interface design, faster simulations, and more user flexibility.

Mr. Matthew McDaniel, lead programmer on the project, said, “We redesigned the simulation software to use the Julia language, which is geared towards efficient numerical computing. As a result, simulation speed is greatly increased, particularly for large virtual populations. We think the combination of this efficient simulation backend with the updated user interface will make for an excellent user experience.”

CSO Dr. Scott Q. Siler of the DILIsym Services division of Simulations Plus said, “The increase in simulation speed in NAFLDsym v2B Beta enhances predictive capabilities and efficiencies. Moreover, the speed boost allows our QSP modeling team to continue to provide powerful insights related to both NASH pathophysiology and potential treatments for it.”

Key features of NAFLDsym v2B Beta include:

• Integration with a modern C++ based graphical user interface (GUI)
• Integration with the open-source Julia Scientific and Machine Learning (SciML) toolkit to solve simulations efficiently
• Results viewer that can open previously exported results files
• Pre-compiled Julia dependencies so users do not need to install a separate Julia environment
• An interactive console application for editing and appending to existing NAFLDsym QSP model equations

Simulations Plus will host a tech talk webinar focused on the technology associated with this release on Tuesday, March 14, 2023, at 11:00 a.m. Eastern Time. Registration for the webinar is available here. Several recent NAFLDsym applications were shared in poster form and can be accessed via the Simulations Plus resource center here.

About Simulations Plus

Serving clients worldwide for more than 25 years, Simulations Plus is a leading provider in the biosimulation market providing software and consulting services supporting drug discovery, development, research, and regulatory submissions. We offer solutions that bridge machine learning, physiologically based pharmacokinetics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. Our technology is licensed and applied by major pharmaceutical, biotechnology, and regulatory agencies worldwide. For more information, visit our website at www.simulations-plus.com. Follow us on LinkedIn | Twitter | YouTube.

The DILIsym Services division of Simulations Plus has developed DILIsym^® and RENAsym™ QST software, as well as NAFLDsym^®, IPFsym^® and ILDsym™ QSP software, to provide the pharmaceutical industry with the QSP/QST tools and resources to efficiently develop safe and effective drug therapies. DILIsym and RENAsym are designed to address drug-induced liver injury (DILI) and drug-induced acute kidney injury, respectively. NAFLDsym, IPFsym, and ILDsym are designed for target or compound evaluation of therapeutic efficacy in nonalcoholic fatty liver disease (NAFLD or NASH), idiopathic pulmonary fibrosis (IPF), and interstitial lung disease (ILD), respectively. More information is available on the company’s web page.

Environmental, Social, and Governance (ESG)

We focus our Environmental, Social, and Governance (ESG) efforts where we can have the most positive impact. To learn more about our latest initiatives and priorities, please visit our website to read our ESG Report.

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995 – With the exception of historical information, the matters discussed in this press release are forward-looking statements that involve a number of risks and uncertainties. Words like “believe,” “expect” and “anticipate” mean that these are our best estimates as of this writing, but that there can be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited to: our ability to maintain our competitive advantages, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, our ability to identify and close acquisitions on terms favorable to the Company, and a sustainable market. Further information on our risk factors is contained in our quarterly and annual reports and filed with the U.S. Securities and Exchange Commission.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230209005324/en/

Simulations Plus Investor Relations

Ms. Renee Bouche

661-723-7723

renee.bouche@simulations-plus.com

Hayden IR

Mr. Brian Siegel

346-396-8696

brian@haydenir.com

Source: Simulations Plus, Inc.

FAQ

What is NAFLDsym v2B Beta and its purpose?

NAFLDsym v2B Beta is a QSP modeling software aimed at supporting the development of treatments for nonalcoholic steatohepatitis (NASH).

What improvements does NAFLDsym v2B Beta offer?

It offers a faster, more intuitive interface and increased simulation speeds, especially for large virtual populations.

When is the tech talk webinar about NAFLDsym v2B Beta?

The webinar is scheduled for March 14, 2023, at 11:00 a.m. Eastern Time.

How does the release of NAFLDsym v2B Beta affect Simulations Plus (SLP) investors?

The release may positively influence investor sentiment by enhancing the company's product offerings in the pharmaceutical modeling sector.